The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
November 18th 2024
Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.
Study: BRCA Mutations More Common in Older Women Diagnosed with Breast Cancer
April 14th 2020Approximately 1 in 40 postmenopausal women diagnosed with breast cancer before the age of 65 had a mutation linked to cancer in the BRCA1 or BRCA2 gene, according to an analysis of data from the Women’s Health Initiative (WHI).
Read More
Community Oncology Alliance Opposes Home Infusion of Cancer Drugs
April 10th 2020COA released a statement explaining that it fundamentally opposes home infusion of chemotherapy, cancer immunotherapy, and cancer treatment supportive drugs due to concerns regarding the safety of patients in such an environment.
Read More
Triple-Negative Breast Cancer: Improved Outcomes and Providing Patient-Centered Care
March 3rd 2020Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.
Read More
FDA Approves sNDA for Neratinib as Therapy for HER2-Positive Metastatic Breast Cancer
February 27th 2020Officials from the FDA have approved a supplemental New Drug Application (sNDA) for neratinib (NERLYNX, Puma Biotechnology) in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.
Read More